Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
56 hedge funds and large institutions have $295M invested in Mersana Therapeutics in 2018 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 9 reducing their positions, and 7 closing their positions.
222% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 9
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
12% more funds holding
Funds holding: 50 → 56 (+6)
4% more capital invested
Capital invested by funds: $283M → $295M (+$12.3M)
0.26% more ownership
Funds ownership: 3.03% → 3.29% (+0.26%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$8.4M |
| 2 |
GTC
Ghost Tree Capital
New York
|
+$4.39M |
| 3 |
BlackRock
New York
|
+$3.8M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$4.86M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$952K |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$423K |
| 4 |
JP Morgan Chase
New York
|
-$403K |
| 5 |
RCP
Rho Capital Partners
New York
|
-$341K |
MRSN Hedge Fund Activity: Q1 2018 in Review
56 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q1 2018, worth a combined $295M — up 4.3% from $283M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new MRSN positions and 7 closed out — a net gain of 6 holders — while 29 added to existing stakes and 9 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $8.4M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $4.86M sold.
- 56 institutional investors held Mersana Therapeutics (MRSN) as of Q1 2018, up from 50 in Q4 2017.
- Funds reported $295M of Mersana Therapeutics stock for Q1 2018, up 4.3% quarter-over-quarter.
- 13 funds opened new Mersana Therapeutics positions in Q1 2018 and 7 closed out, a net change of +6 holders.
- The largest Mersana Therapeutics buyer in Q1 2018 was Wellington Management Group, an estimated $8.4M added.
- The largest Mersana Therapeutics seller in Q1 2018 was Cormorant Asset Management, an estimated $4.86M sold.
Based on aggregated 13F filings for Q1 2018.